ACG 2022

Infection with SARS-CoV-2 has been associated with increased risk for CVD and renal complications.

The first group received high-dose lirentelimab for 24 weeks. The second group received low-dose lirentelimab, while the placebo group received 6 monthly infusions during the 24-week study.

White women were less likely to receive a liver transplant compared with White men, after adjustment for comorbidities and socioeconomic and demographic factors.

Patients taking tradipitant demonstrated significant improvements in nausea compared with placebo.

The patient cohorts were well-balanced at baseline, and, overall, 45.4% had a history of biologic therapy failure.

The retrospective analysis included adult patients with IBD who had outpatient colonoscopies from January 2011 to October 2021 at 3 large academic medical centers.

Although ustekinumab is a common therapy used to treat CD, no serum concentrations that associate with outcomes have been established.

Biologics target inflammatory pathways, allowing for mucosal healing with the end goal of achieving clinical remission.

The study authors concluded that ESG is safe for patients with class III obesity and its efficacy was comparable to SG and RNYB.

Participants had a 5-day placebo run-in period and then were randomly assigned to pancrelipase (72,000 LU/meal; 36,000 LU/snack) or placebo for a 7-day, double-blind period.